Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4473-4478

  Yoshimura, Akinobu ^a,b   Noro, Rintaro ^a   Miyanaga, Akihiko ^a   Mizutani, Hideaki ^a   Kosaihira, Seiji ^a   Minegishi, Yuji ^a   Seike, Masahiro ^a   Hino, Mitsunori ^c   Ando, Masahiro ^d   Nomura, Koichiro ^e   Okano, Tetsuya ^f   Kobayashi, Kunihiko ^f   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^d Tsuboi Cancer Center Hospital   (Japan)

^e TOKYO METROPOLITAN HIROO HOSPITAL   (Japan)

^f SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Alternating chemotherapy; Etoposide; Extensive stage small cell lung cancer; Irinotecan; Phase II study

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; IRINOTECAN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERANCE; EXTENSIVE STAGE LUNG SMALL CELL CANCER; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CISPLATIN; DIARRHEA; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; SEVERITY OF ILLNESS INDEX; SMALL CELL LUNG CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84867775020     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, Crawford J, Randolph JA, Goodlow JL, Broun GO, Omura GA and Greco FA: Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10(2): 282-291, 1992.
2. Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, Shimoyama M and Suemasu K: Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer. J Natl Cancer Inst 83(12): 855-861, 1991.
3. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M and Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small cell lung cancer. N Engl J Med 329(25): 1848-1852, 1993. (Pubitemid 23360484)
4. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, and Johnson BE: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer. J Clin Oncol 12(10): 2022-2034, 1994. (Pubitemid 24356017)
5. Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J and Gandara D: Randomized study of CODE versus alternating CAV/EP for extensive-stage small cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17(8): 2300-2308, 1999. (Pubitemid 29368227)
6. Goldie JH, Coldman AJ and Gudauskas GA: Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66(3): 439-449, 1982. (Pubitemid 12084933)
7. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, Mylonakis N, Provata A, Papadakis E, Klouvas G, Theocharis D, Panousaki E, Boleti E, Sphakianoudis G and Pavlidis N: Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5(7): 601-607, 1994. (Pubitemid 24283096)
8. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K and Takada M: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10(8): 1225-1229, 1992.
9. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, Furuse K and Fukuoka M: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16(3): 1068-1074, 1998. (Pubitemid 28108742)
10. Ando M, Kobayashi K, Yoshimura A, Kurimoto F, Seike M, Nara M, Moriyama G, Mizutani H, Hibino S, Gemma A, Okano T, Shibuya M and Kudoh S: Weekly administration of irinotecan (CPT-11) plus cisplatin for refractory or relapsed small cell lung cancer. Lung Cancer 44(1): 121-127, 2004. (Pubitemid 38317268)
11. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756, 1989. (Pubitemid 19272848)
12. Common toxicity criteria manual, common toxicity criteria, version 2. 1999. (http://ctep.cancer.gov/reporting/ctc.html)
13. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47(1): 207-214, 1981. (Pubitemid 11167383)
14. Hsiang YH, Hertzberg R, Hecht S and Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260(27): 14873-14878, 1985. (Pubitemid 16211028)
15. Ross W, Rowe T, Glisson B, Yalowich J and Liu L: Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Res 44: 5857-5860, 1984. (Pubitemid 15183602)
16. Rasheed ZA and Rubin EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene 22(47): 7296-7304, 2003. (Pubitemid 37487161)
17. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L and Redinbo MR: Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol 339(4): 773-784, 2004. (Pubitemid 38686344)
18. Hofmann GA and Mattern MR: Topoisomerase II in multiple drug resistance. Cytotechnology 12(1- 3): 137-154, 1993.
19. Kaplan E and Gündüz U: Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed Pharmacother 66(1): 29-35, 2012.
20. Chauvier D, Kegelaer G, Morjani H and Manfait M: Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin. J Pharm Sci 91(8): 1765-1775, 2002. (Pubitemid 34810522)
21. Schneider E, Horton JK, Yang CH, Nakagawa M and Cowan KH: Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 54(1): 152-158, 1994. (Pubitemid 24042102)
22. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S and Saijo N: Japan Clinical Oncology Group: Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 346(2): 85-91, 2002. (Pubitemid 34438898)
23. Lara PN Jr., Natale R, Crowley J, Lenz HJ, Redman MW, Carleton JE, Jett J, Langer CJ, Kuebler JP, Dakhil SR, Chansky K and Gandara DR: Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 27(15): 2530-2535, 2009.
24. Lara PN Jr., Chansky K, Shibata T, Fukuda H, Tamura T, Crowley J, Redman MW, Natale R, Saijo N and Gandara DR: Common arm comparative outcomes analysis of phase 3 trials of cisplatin + irinotecan versus cisplatin + etoposide in extensive-stage small cell lung cancer: Final patient-level results from Japan Clinical Oncology Group 9511 and Southwest Oncology Group 0124. Cancer 116(24): 5710-5715, 2010.